Outcomes and Characteristics of Non-Melanoma Skin Cancers in Patients with Myeloproliferative Neoplasms on Ruxolitinib
Rampotas, Alexandros Carter-Brzezinski, Luke Somervaille, Tim C Forryan, James Panitsas, Fotios P Harrison, Claire N Witherall, Ruth Innes, Andrew J Wallis, Louise Butt, Nauman M
Rampotas, Alexandros
Carter-Brzezinski, Luke
Somervaille, Tim C
Forryan, James
Panitsas, Fotios P
Harrison, Claire N
Witherall, Ruth
Innes, Andrew J
Wallis, Louise
Butt, Nauman M
Abstract
Non-melanoma skin cancers in ruxolitinib-treated MPN patients behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis . Vigilant skin assessment, counselling on NMSC risks, and prospective ruxolitinib-NMSC studies are crucial.
MIDER Authors
Citations
Altmetric:
Date
2023-11-14
Type
Correspondence
Subject
Dermatology, Oncology. Pathology.
Collections
Citation
Rampotas A, Carter-Brzezinski L, Somervaille TCP, Forryan J, Panitsas F, Harrison C, Witherall R, Innes AJ, Wallis L, Butt NM, Psaila B, Mead AJ, Carter M, Godfrey AL, Laing H, Garg M, Francis S, Ewing J, Teh CH, Cowen HB, Dyer P, McConville C, Wadelin F, Sahra A, McGregor A, Kulakov E, McLornan DP, Lambert J. Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib. Blood. 2024 Jan 11;143(2):178-182. doi: 10.1182/blood.2023022345.
Journal / Source Title
Blood
DOI
10.1182/blood.2023022345
PMID
37963262
Publisher
Elsevier